Novavax shares plunge after COVID-19 vaccine maker raises doubts over its future – National | 24CA News

Novavax Inc.’s shares plunged 28 per cent in U.S. early buying and selling on Wednesday, a day after the COVID-19 vaccine maker raised doubts about its means to stay in business.

The inventory fell 28.3 per cent to a three-year low of US$6.64 round 10:30 a.m. ET, whereas its Frankfurt-listed shares additionally slumped greater than 27 per cent.

The firm — whose COVID-19 vaccine is its solely marketed product after 35 years in business — on Tuesday flagged vital uncertainty round its 2023 income, funding from the U.S. authorities, and pending arbitration with international vaccine alliance Gavi.

Novavax’s shot, a conventional protein-based vaccine, was pitched as an alternative choice to these from Moderna and Pfizer-BioNTech within the hope it could win over skeptics of newer mRNA know-how, however manufacturing and regulatory delays led to sluggish uptake in key markets.

In the United States, the place the vaccine was licensed in July 2022, solely round 80,000 of its photographs have been administered, in accordance with authorities information.

In Europe, the shot was initially given the inexperienced mild in December 2021. Altogether, solely 219,395 doses have been administered of practically 13 million distributed in EU/EEA international locations, in accordance with information from the European Centre for Disease Control as much as Feb. 23.

3:27Trudeau publicizes plan to supply COVID-19 vaccines in Canada

The vaccine was additionally endorsed by UK regulators final yr. The Department of Health and Social Care didn’t instantly reply to a Reuters question on what number of doses have been deployed to this point.

Novavax, like different COVID vaccine makers, can be gearing up for modifications to the way in which the vaccines are rolled out, with international regulators anticipating vaccination campaigns to be carried out annually, just like flu inoculations.

Companies might want to change their vaccine every year to match circulating strains. Novavax faces near-term dangers as protein-based vaccines take longer to supply than mRNA-based rivals, Novavax CEO John Jacobs has mentioned.

Jefferies’ analysts mentioned they have been decreasing Novavax’s peak COVID-19 market share to fifteen from 25 per cent, and reduce their value goal on the U.S. inventory to US$68 from US$90. B Riley Securities’ analysts additionally slashed their value goal to $10 from $29.

The challenges forward of Novavax are unsurprising given the very late entry of its COVID-19 vaccine as international locations transition to a post-pandemic setting, mentioned Lee Brown, international sector lead for healthcare at analysis agency Third Bridge.

“While there is the potential for a substantial booster market … we don’t expect Novavax to be a major player in the booster opportunity.”

As of final shut, Novavax’s U.S.-listed shares have been down 97 per cent from their February 2021 report excessive of US$331.68.